KRAS and cancer: Finally, a nanoparticle-formulated mRNA based cancer vaccine (V941) that targets four of the most prevalent occurring KRAS mutations (c.35G > A, p.G12D; c.35G > T, p.G12V; c.38G > A, p.G13D and c.34G > T, p.G12C) is in developing stages as monotherapy or in combination with pembrolizumab in NSCLC, CRC or PDAC patients (ClinicalTrials.gov NCT03948763).